Rare association in elevated liver enzymes: celiac disease and primary biliary cirrhosis

Yıl 2014, Cilt: 13 Sayı: 2, 73 - 74, 01.08.2014

Mesut Sezikli - Züleyha Akkan Çetinkaya Göktuğ Şirin - Hayrünnisa Sezikli - Didem Eroğlu -

Öz

Elevated liver enzymes is a common presentation in our daily clinical practice. Celiac disease and primary biliary cirrhosis are diseases of different organs. However, they share a similarity in pathogenesis. In this report, we aimed to show that there may be more than one cause of elevated liver enzymes in any patient.

Anahtar Kelimeler

-

Karaciğer enzim yüksekliğinde nadir birliktelik: Çölyak ve primer biliyer siroz

Öz

Karaciğer enzim yüksekliği günlük pratikte sık karşılaştığımız bir sorundur. Çölyak hastalığı ve primer biliyer siroz farklı anatomik bölge tutulumları ile seyretse de etiopatogenez benzerliği mevcuttur. Bu olgumuzda karaciğer enzim yüksekliğinin birden fazla nedeni olabileceğini belirtmek istedik.

Kaynakça

• Farrell RJ, Kelly CP. Celiac sprue-current concepts. N Engl J Med 2002; 346:180-8.
• Hu WT, Murray JA, Greenway MC, et al. Cognitive impairment and celiac disease. Arch Neurol 2006; 63:1440-6.
• Zone JJ. Skin manifestations of celiac disease. Gastroenterology 2005; 128 (Suppl 1):S87-9.
• Frustaci A, Cuoco L, Chimenti C, et al. Celiac disease associated with autoimmune myocarditis. Circulation 2002; 105:2611-8.
• Freeman HJ. Hepatic manifestations of celiac disease. Clin Exp Gas- troenterol 2010; 3:33-9.
• Mirzaagha F, Azali SH, Islami F, et al. Coeliac disease in autoim- mune liver disease: a cross-sectional study and a systematic review. Dig Liver Dis 2010; 42:620-3.
• Volta U, De Franceschi L, Lari F, et al. Coeliac disease hidden by cryptogenic hypertransaminasaemia. Lancet 1998; 352:26-9.
• Bardella MT, Vecchi M, Conte D, et al. Chronic unexplained hyper- transaminasemia may be caused by occult celiac disease. Hepatol- ogy 1999; 29:654-7.
• Bogdanos DP, Baum H, Grasso A, et al. Microbial mimics are major targets of cross reactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. J Hepatol 2004; 40:31-9.
• Maddala YK, Jorgersen YA, Angulo P, et al. Open label pilot study of tetracycline in the treatment of primary biliary cirrhosis. Am J Gastroenterol 2004; 99:566-7.
• Kaplan MM. Novospingobium aromaticivorans: a potential initiator of primary biliary cirrhosis. Am J Gastroenterol 2004; 99:2147-9
• Bogdanos D, Pusl T, Rust C, et al. Primary biliary cirrhosis following Lactobacillus vaccination for recurrent vaginitis. J Hepatol 2008; 49:466-73.
• Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N. Engl J Med 2005; 353:1261-73.
• Prince MI, C hetwynd A, Craig WL, et al. Asymptomatic primary bili- ary cirrhosis; clinical features, prognosis, and symptom progression in a large population based cohort. Gut 2004; 53:865-70.
• Logan RF, Ferguson A, Finlayson ND, Weir DG. Primary biliary cir- rhosis and celiac disease: an association? Lancet 1978; 1:230-3.
• Sorensen HT, Thulstrup AM, Blomqvist P, et al. Risk of primary bili- ary liver cirrhosis in patients with celiac disease: Danish and Swed- ish cohort study. Gut 1999; 44:736-8.
• Feld JJ, Meddings J, Heathcote EJ. Abnormal intestinal permeability in primary biliary cirrhosis. Dig Dis Sci 2006; 51:1607-13.
• Selmi C, Gershwin ME. Bacterial and human autoimmunity: the case of primary biliary cirrhosis. Curr Opin Rheumatol 2004; 16:406-10.
• Murray JA, Watson T, Clearman B, Mitros F. Effect of a gluten-free diet on gastrointestinal symptoms in celiac disease. Am J Clin Nutr 2004; 79:669-73.
• West J, Logan RFA, Smith CJ, et al. Malignancy and mortality in people with celiac disease: population based cohort study. BMJ 2004; 329:716-20.